Phase 2 N=32 Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 9.5; 10.1 Median months subjects survived
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
HER2+/HR+ Breast Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 1 Participants
Phase 2 N=19 Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants
Phase 2 N=51 FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIIA Lung Non-Small Cell Cancer AJCC v7 · Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Primary: Overall Survival (OS) Rate — 54.2 percentage of patients
Phase 2 N=55 To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
Covid19
Primary: Median Time to Sustained Clinical Response — 6; 8 Days
Phase 2 N=16 Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Primary: Parts A, B, and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 62; 6; 3 Participants
Phase 2 N=42 Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants
Phase 2 N=134 A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: The Primary Outcome is the Change in Best-corrected Visual Acuity (BCVA) Using the Electronic Visual Acuity (EVA) Technology at Month 12. — 1; 1; 3; 1 participants
Phase 2 N=45 Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition
Bacterial Vaginosis · HIV Infections
Primary: Number of Participants With Genital Tract Inflammation — 3; 2 Participants
Phase 2 N=20 Biomarker Changes and Anxiolytic Effects-Phase 2
Pharmacokinetics
Primary: Mean PRKACA Change — 7224.56; 5348.93; 6307.21; 6495.7 relative fluorescence units
Phase 2 N=35 Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Non-Small Cell Lung Cancer
Primary: Phase Ib: Maximum Tolerated Dose — 4; 200 mg
Phase 2 N=110 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Breast Cancer · Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Rate and Severity of Treatment-emergent Adverse Events ≥ Grade 3 Attributed to Study Drug Using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03)…
Phase 2 N=55 First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
Hepatitis B
Primary: The Incidence of Participants With Treatment-Emergent Adverse Events (TEAEs) and ≥Grade 3 Study Vaccine-related Adverse Events Following Study Vaccination — 1; 1; 2; 1…
Phase 2 N=138 A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain
Chronic Low-back Pain
Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.24; -1.63 score on a scale
Phase 2 N=40 Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer
Locally Advanced Breast Cancer · Metastatic Breast Cancer
Primary: Percentage of Patients Without Disease Progression — 7; 8 Participants